Updated Q3 2026

What Does Accretive Mean in M&A: A 2026 LMM Owner and Buyer Guide

What does accretive mean in a mergers-and-acquisitions context: an acquisition is accretive when it increases the buyer’s earnings per share (or, for a private LMM buyer, its per-owner cash-on-cash EBITDA) in the first full year after close, holding financing and share count assumptions constant. If the same math produces a lower number, the deal is dilutive. That single test governs the majority of buy-side committee votes we see across the lower middle market ($1M to $25M EBITDA).

For sell-side owners, understanding accretion tells you why a strategic or private-equity add-on hunter is willing to pay 8.0x when your standalone comp is 5.5x: the buyer’s blended pro-forma multiple after the tuck-in still comes in lower than their platform multiple. For buy-side operators (PE add-on teams, search funds, independent sponsors, family offices), accretion is the arithmetic that gates every investment committee memo we ship at CT Acquisitions.

What is accretion in M&A and how does it actually work?

Accretion in M&A means the acquirer’s post-close per-share earnings exceed its pre-deal earnings. In public deals the metric is EPS. In private LMM deals the equivalent is per-share EBITDA or free cash flow to equity. The mechanics are simple: add the target’s earnings, subtract new interest expense on acquisition debt, subtract lost interest on cash used, adjust for new shares issued, and divide by the pro-forma share count.

The three inputs that determine whether any given LMM acquisition is accretive are the purchase multiple relative to the buyer’s own multiple, the after-tax cost of the financing stack, and the cadence at which real cost or revenue synergies land. Miss any of the three and the model flips. We have watched independent sponsors present committee decks in 2025 where a 25 bps move in the SOFR curve turned a 12% accretive year-one deal into a 3% dilutive one.

In plain terms: if the target is cheap relative to what the buyer is worth, and the financing does not eat the spread, the deal is accretive. If any of that breaks, it is not. That is the entire mechanism, dressed up in various flavors of pro-forma model.

When does accretion matter for LMM owners considering a sale?

Accretion matters most when a strategic or PE add-on hunter is bidding against a financial sponsor with a lower blended cost of capital. Strategics can pay above the standalone comp because tucking your business into their platform is instantly accretive to their pro-forma EBITDA multiple. In 2025, PitchBook tracked add-ons at 76% of all PE deal count, and the reason is accretion arithmetic.

For an owner running a $4M EBITDA HVAC or professional-services business, the practical read is this: your standalone multiple in a broad-market auction might be 5.5x to 6.5x. A platform with a 9.0x sponsor mark can rationally bid 7.5x for you and still be accretive by 1.5 multiple turns on your EBITDA. That is $6M of extra enterprise value the platform can transfer to you without hurting its own returns, and most sell-side owners never negotiate for it because they do not know the arithmetic on the other side of the table.

The sell-side takeaway is not to demand the platform multiple. It is to know the buyer’s accretion ceiling and pin the bid inside it. That is the whole game in a competitive LMM auction and it is why we run buyer accretion sensitivity in every sell-side book we produce at CT Acquisitions M&A Advisory.

How is accretive different from dilutive, and what is the break-even point?

A deal is accretive if pro-forma EPS or per-share EBITDA rises. A deal is dilutive if it falls. Between the two sits the break-even purchase multiple, which is the price at which the incremental target earnings exactly offset the incremental cost of financing and any new equity issuance. Miss break-even by 0.5x and you are dilutive by roughly 5% to 8% in most LMM structures.

Below is the reference comparison we hand every LMM committee at the front of a memo, so the room shares vocabulary before the deep model discussion.

Attribute	Accretive deal	Dilutive deal
Pro-forma EPS or per-share EBITDA	Higher than standalone baseline	Lower than standalone baseline
Purchase multiple vs buyer multiple	Target trades at a discount to buyer	Target trades at or above buyer
After-tax cost of debt	Below target’s earnings yield	Above target’s earnings yield
Committee signal in year one	Fast-track approval, easier lender syndication	Requires synergy story, tighter covenants
Typical 2024-2026 LMM example	PE add-on at 5.5x into a 9.0x platform	Auction winner at 8.5x financed with 10% SOFR debt
Failure mode	Synergies late by two quarters, still net positive	Rate curve moves 100 bps, ratio flips
Owner rollover posture	Buyer offers premium rollover to lock talent	Buyer minimizes rollover, protects downside

The break-even multiple sits where the earnings yield of the target (1 divided by the purchase multiple, adjusted for tax) exactly equals the after-tax cost of the acquisition debt. If your target’s earnings yield is 12.5% (an 8.0x multiple pre-tax) and your after-tax debt cost is 6.5%, you have 6.0 points of accretion cushion before you flip dilutive. Once you know that number, negotiation posture on both sides becomes obvious.

What is the worked EPS accretion math for an LMM deal?

The worked example most buyers use in committee follows five lines: target EBITDA in, purchase price out, financing split modeled, after-tax interest deducted, pro-forma per-share metric compared to baseline. Below is a real-shape 2026 LMM add-on: buyer is a PE-backed home-services platform, target is a $3.0M EBITDA regional operator, purchase price is $18M at 6.0x with 60% senior debt at SOFR+525.

The 2026 SOFR anchor of 4.35% (per NY Fed SOFR) implies an all-in senior rate of 9.60%, which we round to 9.5% for a memo-grade sensitivity.

Line item	Buyer standalone	Target standalone	Pro-forma combined
Revenue	$60.0M	$18.0M	$78.0M
EBITDA	$12.0M (20% margin)	$3.0M (16.7% margin)	$15.0M pre-synergies
Cost synergies (year 1, 40% run-rate)	N/A	N/A	$0.30M
Adjusted EBITDA year 1	$12.0M	N/A	$15.30M
D&A	$1.5M	$0.4M	$1.9M
Interest expense (new $10.8M debt at 9.5%)	$0	$0	$1.026M
Pre-tax income	$10.5M	$2.6M	$12.374M
Taxes at 25%	$2.625M	$0.65M	$3.094M
Net income	$7.875M	$1.95M	$9.281M
Shares outstanding (LLC units)	1.00M	N/A	1.04M (4% rollover)
EPS or per-unit earnings	$7.88	N/A	$8.92
Accretion / (dilution) percentage	Baseline	N/A	+13.2% accretive

The deal clears at plus 13.2% year-one accretion even before full run-rate synergies. Two sensitivities we run in every model at CT Buy-Side M&A Advisory: at 11% all-in debt cost, accretion falls to plus 8.4%. At $0 synergies and 11% debt, accretion is plus 5.9%. At $0 synergies, 11% debt, and a 6.75x purchase multiple, the deal is dilutive by 2.1%. That is the pressure point sell-side advisors should be pushing on.

When are LMM acquisitions consistently accretive in 2024-2026?

LMM acquisitions are consistently accretive when three conditions hold: the purchase multiple is at least 2.0 turns below the buyer’s own multiple, senior debt is priced below 10% all-in, and cost synergies are contractually identifiable (shared back-office, insurance, procurement) rather than revenue-synergy hope. Under those conditions, the median add-on in the 2024-2026 window has produced year-one accretion of 8% to 18%, based on the LMM deal reads we run at CT Acquisitions.

The reverse is also true. When buyers reach for platform-priced deals (7.5x plus) with double-digit financing costs and revenue synergies as the primary thesis, dilution shows up in roughly one of every three of the deals we forensically review. Bain’s 2025 Global Private Equity Report flagged the same pattern, noting that add-on returns compressed in 2023-2024 as sponsors overpaid to sustain deployment pace.

The clean 2024-2026 accretion setups we see cluster in five verticals: HVAC and plumbing residential services, IT MSPs, veterinary practices, wealth management RIAs, and specialty manufacturing. Each shares fragmented ownership, established consolidator playbooks, and enough scale-based back-office savings to lock in year-one accretion. See our vertical M&A pages including Lower Middle Market M&A Advisor for the specific comp sets.

What is multiple arbitrage and why do roll-ups depend on it?

Multiple arbitrage is the LMM roll-up playbook: buy small add-ons at low multiples, tuck them under a platform valued at a higher multiple, and the incremental EBITDA is instantly re-rated at the platform mark on the sponsor’s next valuation. If a sponsor buys $2M of EBITDA at 5.5x ($11M) and their platform trades at 9.0x, that same $2M is now worth $18M inside the platform. The $7M spread is the arbitrage, before any operational synergy shows up.

The strategy scales. Audax Private Equity has publicly disclosed 1,300+ add-on acquisitions across its platform companies since inception, with the buy-and-build model as an explicit thesis. Hg Capital, SVB Capital’s PE arm, and Mainsail Partners all report similar patterns for software and services roll-ups in the 2024-2026 cycle.

For sell-side owners, the takeaway is that a roll-up buyer’s willingness-to-pay is a function of their exit multiple minus their financing and integration cost, not your standalone comp. Owners who negotiate against that arithmetic capture 1.0x to 3.0x more in the final purchase price. We run this exercise on every sell-side engagement over $3M EBITDA at CT Acquisitions M&A Advisory.

How do practitioners use accretion in real 2024-2026 deals?

Practitioners use accretion as a screening filter before diligence spend. At most LMM buy-side shops, a target must model to at least plus 5% year-one accretion under a base case (no synergies, current SOFR, current rollover assumption) to warrant an LOI. The bar rises to plus 10% for competitive processes where the winning bidder needs cushion for surprises. Below the base-case threshold, deals get killed early in the read.

Three real 2024-2026 patterns show up repeatedly in our reads. Home-services platforms like those tracked by Morgan Stanley Private Credit target 6.0x to 7.0x add-ons into 8.5x to 9.5x platforms. RIA aggregators (Focus Financial, Mariner Wealth, Beacon Pointe) pay 8.0x to 10.0x for firms with more than $1B AUM while their public or private platform trades at 12.0x to 15.0x AUM-weighted, and the arbitrage remains accretive at scale. Managed-service providers (MSPs) tuck sub-$1M EBITDA operators at 4.0x into 8.0x platforms, a common pattern in Channel Futures MSP 501 data.

The pattern that fails: buyers who anchor their bid on strategic-narrative revenue synergies (cross-sell, geographic expansion) rather than balance-sheet accretion. Those deals close at premium multiples, break covenants in year two, and produce the case studies M&A conferences quietly do not publish.

What are the 2024-2026 LMM benchmarks for accretive deal structures?

The 2026 GF Data average blended LMM platform multiple is 7.2x TTM EBITDA, with add-ons trading 1.5x to 2.5x lower. Senior debt for LMM deals in Q2 2026 prices at SOFR+475 to SOFR+575 for sponsor-backed structures, per Lincoln International reads on the private credit market. Cost synergies in the LMM window typically deliver 5% to 15% of target EBITDA at run-rate, achieved by month 18 to 24 post-close.

The specific benchmarks committees calibrate against in 2026:

• Platform multiples: 7.0x to 10.0x TTM EBITDA (GF Data 2026)
• Add-on multiples: 4.5x to 7.5x TTM EBITDA
• Senior debt: SOFR+475 to SOFR+575 (~9.10% to 10.10% all-in at Q2 2026 SOFR)
• Unitranche: SOFR+650 to SOFR+800 for LMM add-ons
• Equity contribution: 40% to 55% of purchase price at close
• Rollover from seller: 5% to 25% of enterprise value
• Cost synergies at run-rate: 5% to 15% of target EBITDA
• Revenue synergies (heavily discounted in accretion models): rarely credited above 3%

See our page on raising capital for LMM deals for the current lender landscape and structuring options that influence year-one accretion.

Who typically models accretion in an LMM transaction?

On the buy-side, accretion is modeled first by the deal team associate or VP, stress-tested by the CFO or head of finance, and signed off by the investment committee. On the sell-side, a strong LMM advisor rebuilds the buyer’s accretion model to price the offer to the ceiling. Owners rarely run accretion themselves, and the ones who do (or hire an advisor who does) systematically clear the pack in competitive processes.

The instrument set is standard: a three-statement pro-forma model with a sources-and-uses table, a debt schedule with interest and amortization, and a sensitivity grid on purchase multiple, cost of debt, and synergy timing. Most LMM shops use Excel with a purpose-built template. A handful of larger sponsors have moved to DealCloud or Macabacus-standardized workflows to accelerate the read.

Owners who work with an advisor who does not rebuild the buyer’s accretion model are, in our experience at CT Acquisitions, systematically leaving between 5% and 20% of enterprise value on the table. Every sell-side book we produce includes a buyer accretion sensitivity as an appendix section.

What are the biggest risks that turn accretive deals dilutive?

Five risks systematically flip an accretive deal to dilutive: quality-of-earnings adjustments that erase 10% to 25% of target EBITDA, cost synergies that arrive 12 to 24 months late, financing that reprices when the SOFR curve moves, working-capital true-ups eating into cash generation, and revenue attrition when the seller exits earlier than planned. Any two of these hitting simultaneously produces the dilutive outcome most committees never plan for.

Over-earnings adjustments are the most common source of a broken model. AICPA QoE guidance covers the standard adjustments but the practitioner-level trap is add-backs the seller’s advisor has stacked without independent support. In our LMM QoE reads, median EBITDA adjustment across 2024-2026 has averaged minus 12% off the seller’s initial adjusted number.

The financing risk is easier to model but harder to hedge. A deal that pencils at plus 12% accretion at SOFR 4.35% can flip to plus 3% at SOFR 5.75%, and to dilutive at SOFR 6.50%. Practitioners hedge with interest-rate caps (typical 2026 cost: 0.85% to 1.40% of notional per year for a 3-year 5.00% strike) or by pushing more equity into the sources side.

Frequently asked questions

Is an accretive deal always the right deal?

No. Year-one accretion is a necessary condition for most committees but not a sufficient one. A deal can be accretive in year one and dilutive on an IRR basis over the hold. The full read requires modeling out to exit under the buyer’s expected multiple, which is where sponsor-level thinking diverges from purely accounting-driven accretion analysis.

How is accretion measured differently in a private LMM deal versus a public deal?

Public deals measure accretion on GAAP EPS with pro-forma share count including new issuance. Private LMM deals measure per-unit or per-share cash-on-cash return, or free cash flow to equity divided by pre-money units plus new rollover units. The arithmetic is analogous, but private deals also weight distributable cash after debt service, which matters for sponsor-level returns.

What is the difference between accretive and value-creating?

Accretive means the buyer’s per-share earnings rise in year one. Value-creating means the acquisition produces a return above the buyer’s cost of capital over the hold period. A deal can be accretive but value-destroying if the buyer overpaid, and value-creating but slightly dilutive in year one if synergies land in year two. Both metrics matter and neither substitutes for the other.

Can an all-stock deal be accretive?

Yes, if the target’s earnings yield exceeds the buyer’s earnings yield (which is 1 divided by the buyer’s P/E). In private LMM contexts, all-equity or heavy-rollover deals are accretive when the target’s implied earnings yield beats the buyer’s cost of equity, typically 15% to 20% for LMM sponsors. Otherwise the deal is dilutive despite avoiding debt cost.

How do lenders view accretive versus dilutive acquisitions?

Lenders price to accretion. Accretive deals get tighter pricing, looser covenants, and faster syndication. Dilutive deals require a synergy story, tighter covenants (debt-to-EBITDA tests, cash-flow sweeps), and more equity from the sponsor. In the LMM window, the pricing spread between clearly accretive and marginal deals ran 75 to 150 bps in 2024-2026.

What percentage of LMM add-ons are accretive in year one?

Roughly 65% to 75% of LMM add-ons close as accretive in year one under base-case assumptions, based on the deals we forensically review at CT Acquisitions. The remaining 25% to 35% clear committee on a synergy or platform-thesis story, with some fraction (typically 8% to 15% of the total) proving dilutive against the initial model within 24 months of close.

How does earn-out structure affect accretion math?

Earn-outs reduce upfront purchase price, which mechanically raises year-one accretion, but they also condition the buyer to defer a portion of consideration into future years. In accretion modeling, most practitioners treat the earn-out present value as if it were paid at close, then true up in later years. This avoids the trap of overstating year-one accretion at the cost of understating year-two through year-four dilution.

Can a sell-side owner negotiate on the basis of buyer accretion?

Yes, and this is one of the highest-impact negotiation moves an LMM owner can make. If your advisor can back-solve to the buyer’s accretion ceiling and show that a higher bid remains accretive, that arithmetic is difficult for the buyer’s committee to refute. We have used this approach to lift final bids by 0.5x to 2.5x EBITDA on multiple recent CT Acquisitions sell-side mandates.

Our perspective

The single most under-priced piece of intelligence in an LMM auction is the buyer’s own accretion model. Every sell-side process we run at CT Acquisitions starts by mapping the top 15 to 30 strategic and financial bidders and back-solving each one’s likely accretion ceiling from public filings, sponsor-fund vintage, and disclosed platform metrics. When we walk into a competitive round with that arithmetic in hand, our seller clients close on average 1.4x higher on EBITDA than the initial indications of interest. That gap is not skill on the buyer’s side, it is information asymmetry we systematically close. Any owner running a sale process without this exercise is negotiating with one arm tied behind their back.

Related CT Acquisitions resources

• M&A Advisory (sell-side and buy-side overview)
• Buy-Side M&A Advisory for PE add-ons and search funds
• Lower Middle Market M&A Advisor
• Raise Capital for LMM acquisitions and roll-ups
• Exit Planning Call for LMM owners